Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

NEOGENOMICS, INC.

(NEO)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/13/2021 10/14/2021 10/15/2021 10/18/2021 10/19/2021 Date
42(c) 43.6(c) 43.38(c) 43.65(c) 44.315 Last
526 170 942 747 934 293 610 696 117 913 Volume
+2.76% +3.81% -0.50% +0.62% +1.52% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 498 M - -
Net income 2021 16,3 M - -
Net Debt 2021 157 M - -
P/E ratio 2021 373x
Yield 2021 -
Sales 2022 580 M - -
Net income 2022 -60,8 M - -
Net Debt 2022 155 M - -
P/E ratio 2022 -90,9x
Yield 2022 -
Capitalization 5 368 M 5 368 M -
EV / Sales 2021 11,1x
EV / Sales 2022 9,52x
Nbr of Employees 1 700
Free-Float 96,0%
More Financials
Company
NeoGenomics, Inc. is an operator of a network of cancer-focused testing laboratories. The Company’s customers include Clinical and Pharma. Its Clinical customers include community-based pathology practices, oncology groups, hospitals and academic centers. Its Pharma customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials. The... 
More about the company
Ratings of NeoGenomics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about NEOGENOMICS, INC.
04:46aNEOGENOMICS : Subsidiary Enters Into Clinical Trial Collaboration With Princess Margaret C..
MT
02:12aNEOGENOMICS' : Liquid Biopsy Subsidiary Inivata Announces Clinical Collaboration With Prin..
PU
10/14Health Care Stocks Moderate Slightly in Afternoon Trading
MT
10/14NEOGENOMICS : Shares Rise After Raymond James Upgrade
MT
10/14Health Care Stocks Keeping Pace With Rising Thursday Markets
MT
10/14NEOGENOMICS : Raymond James Upgrades NeoGenomics to Outperform from Market Perform, Sets $..
MT
10/13NEOGENOMICS : Schedules its Third Quarter 2021, Earnings Release for November 4, 2021
PU
10/12NEOGENOMICS : Appoints Lead Independent Director Lynn Tetrault as Non-Executive Chair. Dou..
PU
10/12NEOGENOMICS INC : Change in Directors or Principal Officers, Financial Statements and Exhi..
AQ
10/12NeoGenomics, Inc. Announces Board Changes
CI
10/12NEOGENOMICS : Announces Board of Directors' Transition
PU
10/01Health Care Stocks Broadly Higher Late Friday
MT
10/01Guardant Health Reportedly Exploring an Acquisition of NeoGenomics
CI
10/01MARKET CHATTER : Guardant Health's Shares Sink on Reports of NeoGenomics Takeover Plans; S..
MT
10/01GUARDANT HEALTH : Reportedly Mulls Acquisition of Diagnostics Services Provider NeoGenomic..
MT
More news
News in other languages on NEOGENOMICS, INC.
04:46aUne filiale de NeoGenomics s'engage dans une collaboration d'essais cliniques avec le P..
10/14Les actions du secteur de la santé se modèrent légèrement dans les échanges de l'après-..
10/14Les actions de NeoGenomics augmentent après la mise à niveau de Raymond James
10/14Les actions du secteur de la santé suivent le rythme de la hausse des marchés jeudi.
10/01Les actions du secteur de la santé en hausse vendredi soir
More news
Analyst Recommendations on NEOGENOMICS, INC.
More recommendations
Chart NEOGENOMICS, INC.
Duration : Period :
NeoGenomics, Inc. Technical Analysis Chart | NEO | US64049M2098 | MarketScreener
Technical analysis trends NEOGENOMICS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 43,65 $
Average target price 56,45 $
Spread / Average Target 29,3%
EPS Revisions
Managers and Directors
Mark Mallon Chief Executive Officer & Director
George A. Cardoza President & Chief Operating Officer-Lab Operations
Kathryn B. McKenzie Chief Financial Officer
Lynn A. Tetrault Non-Executive Chairman
Steven A. Ross Chief Information Officer & Vice President
Sector and Competitors